α-Amylase/α-Glucosidase-IN-12

Cat. No.: HY-163439: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC₅₀ of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research.

Para uso exclusivo en investigación. No vendemos a pacientes.

α-Amylase/α-Glucosidase-IN-12 Estructura química

Tamaño		Stock
MOQ		Minimum order quantity
50 mg		Obtener un presupuesto
100 mg		Obtener un presupuesto
250 mg		Obtener un presupuesto
Other size		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Recomendaciones destacadas

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn	α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC₅₀ of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research^[1].
IC₅₀ & Target	IC50: 34.52 nM (α-Glucosidase), 24.62 nM (α-Amylase)^[1]
In Vitro	The Ki value of α-Amylase/α-Glucosidase-IN-12 and α-glucosidase is 33.85 nM^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. α-Amylase/α-Glucosidase-IN-12 Related Antibodies
Peso molecular	430.41
Fòrmula	C₁₉H₁₃F₃N₆OS
SMILES	O=C(NC1=CC=C(C(F)(F)F)C=C1)CSC2=NN=C3N2N=C(C4=CC=CC=C4)C=N3
Envío	Room temperature in continental US; may vary elsewhere.
Almacenamiento	Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación	Ficha de datos (271 KB) Instrucciones de manejo (2659 KB)
Referencias	[1]. Seyfi S, et al. Synthesis, biological activities, and molecular docking studies of triazolo[4,3-b]triazine derivatives as a novel class of α-glucosidase and α-amylase inhibitors. Arch Pharm (Weinheim). 2024 Mar 19:e2300628. [Content Brief]